Want to join the conversation?
$ILMN still expects FY16 revenue growth of about 12% and non-GAAP EPS of $3.48-3.58. For 3Q16, the company projects revenue of $625-630MM. CEO Francis deSouza said $ILMN will continue to focus on execution to deliver the sequential growth it is expecting in 2H16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.